You are here

Apricity Therapeutics

Company Information
Address
953 Indiana Street
San Francisco, CA 94107
United States



Information

DUNS: 078401096

# of Employees: 4


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: Yes



Award Charts




Award Listing

  1. Drug Transporters in Farm Animals

    Amount: $168,000.00

    Drug Transporters in Farm Animals Membrane transporters in the ATP Binding Cassette Family (ABC) play critical roles in cellular efflux of endogenous metabolites as well as xenobiotics including presc ...

    SBIRPhase I2020Department of Health and Human Services Food and Drug Administration
  2. A Transporter Platform Technology For Discovery of Drugs to Treat Autoimmune Disease

    Amount: $223,334.00

    Project Summary Abstract ! The longterm goal of Apricity TherapeuticsIncApricityis to target pharmacological transporters in the Solute Carrier superfamilySLCto treat diseases for which there are no a ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  3. Development of a Pharmacoprotector for Platinum Toxicities

    Amount: $225,000.00

    Project Summary Abstract Reducing drug toxicity while enhancing efficacy represents a major goal of precision medicine In this SBIR Phase I application we propose a novel concept in drug therapy tha ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  4. Development of Transporter Targeted Platinum Drugs for Glioblastoma

    Amount: $216,990.00

    DESCRIPTION provided by applicant The blood brain barrier BBB the restrictive endothelium of the vasculature in the brain represents a major challenge for the development of drugs to treat diso ...

    SBIRPhase I2016Department of Health and Human Services National Institutes of Health
  5. Development of Transporter Targeted Platinum Drugs for Pediatric Tumor

    Amount: $190,000.00

    Project Summary/Abstract Childhood cancers remain a leading cause of death in children between 1 and 14 years of age. Of the childhood cancers, solid tumors are among the least curable. The goal of th ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
  6. Development of transporter targeted platinum drugs for neuroblastoma

    Amount: $172,738.00

    DESCRIPTION (provided by applicant): Neuroblastoma (NB) is the most common solid tumor in children. Cisplatin, a first generation platinum analog, is first-line therapy in the treatment f NB and toget ...

    SBIRPhase I2012Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government